First steps to implement the new BTS/NICE/SIGN asthma guideline
This is a high-level summary of what the new BTS/NICE/SIGN Asthma: diagnosis monitoring and chronic asthma management guideline means for you as a primary healthcare professional and what steps you need to take to implement it effectively.
This document is a distillation of the new guidance to provide distinct advice on the changes on the diagnosis and management to asthma. It is not intended to be a comprehensive guide of the new guideline, neither does it cover all non-pharmacological treatments or on-going monitoring. We recommend you use the links to resources provided throughout to obtain more detailed information and guidance.
It focuses on the following aspects of the patient journey for both adults and children and young people:
- Diagnosis of asthma: In newly diagnosed patients
- Treatment of asthma: In newly diagnosed patients
- Management and treatment of asthma: In adults and CYP (5+) with an existing diagnosis
- Management and treatment of asthma: In children under 5
- Monitoring and self-management: In all patients
On Demand webinar: The new BTS/SIGN/NICE guideline for asthma: What it means for you
AstraZeneca has provided sponsorship towards this independent Programme and has had no involvement in its creation or organisation
Are you ready for the new asthma guideline?
New BTS/SIGN/NICE Guideline on Asthma: diagnosis, monitoring and chronic asthma management 2024
Tailoring Inhaler Devices
Inhalation is the main route for administration of drugs for conditions such as asthma or chronic obstructive pulmonary disease. The advantage of administering drugs by inhaler is that drugs are delivered directly to the site of action within the airways. The onset of action is rapid and systemic adverse effects are minimised. However, for an inhaler to be effective the correct drug must be prescribed and the device must be used correctly. Poor inhaler technique is common.